Quantitative MR in multi-center clinical trials

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 2, 2010, Pages 279-288

  Ashton, Edward ^a  

^a VirtualScopics LLC   (United States)

Author keywords

Clinical trials; MRI; Protocol design; Protocol harmonization

Indexed keywords

GADOLINIUM; GLYCOSAMINOGLYCAN; LIPID;

ARTICULAR CARTILAGE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; HIPPOCAMPUS; HUMAN; IMAGING SYSTEM; JOINT RADIOGRAPHY; LIPID LIVER LEVEL; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW;

ALGORITHMS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 75849121435     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22022     Document Type: Review

References (61)

1. Harris J, Frank J, Patronas N, McFarlin D, McFarland H. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548-555.
2. Paty D, Li D. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
3. Marckman P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362.
4. Daffertshofer M, Gass A, Ringleb P, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a Phase II clinical trial. Stroke 2005;36:1441-1446.
5. Warach S. Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med 2001;2:38-44.
6. Liu G, Rugo H, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a Phase I study. J Clin Oncol 2005;23:5464-5473.
7. Tuszynski M, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11:551-555.
8. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006;114:I-101-I-107.
9. Therasse P, Arbuck E, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
10. Sharp J, Lidsky M, Collins L, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-720.
11. Miller D, Khan O, Sheremata W, et al. A controlled trial of natalizumab for relapsingmultiple sclerosis. N Engl JMed 2003;348:15-23.
12. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur J Cancer 2005;41:1291-1299.
13. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-2033.
14. Laham R. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. J Am Coll Cardiol 2000;36: 2132-2139.
15. Herbst R, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256.
16. Anderson H, Yap J, Miller M, Robbins A, Jones T, Price P. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-2830.
17. Jackson A, Haroon H, Zhu X, Li K, Thacker N, Jayson G. Breathhold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 2002;15:164-173.
18. Tofts P. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imag 1997;7:91-101.
19. Shi W, Siemann D. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 2005;25:3899-3904.
20. Raynauld J, Pelletier J, Berthiaume M, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004;50:476-487.
21. Ashton E, Takahashi C, Berg M, Goodman A, Totterman S, Ekholm S. Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging 2003;17:300-308.
22. Takaya N, Cai J, Ferguson M, et al. Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 2006;24:203-210.
23. Doria A, Castro C, Kiss M, et al. Inter- and intrareader variability in the interpretation of two radiographic classification systems for juvenile rheumatoid arthritis. Pediatr Radiol 2003;33: 673-681.
24. Lurie J, Tosteson A, Tosteson T, et al. Reliability of readings of magnetic resonance imaging features of lumbar spinal stenosis. Spine 2008;33:1605-1610.
25. Fu L, Fonov V, Pike B, Evans A, Collins D. Automated analysis of multi site MRI phantom data for the NIHPD project. Lect Notes Comput Sci 2006;4191:144-151.
26. Collins J. Imaging and other biomarkers in early clinical studies: ones step at a time or re-engineering drug development? J Clin Oncol 2005;23:5417-5419.
27. Jack C, Bernstein M, Fox N, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685-691.
28. Eckstein F, Maschek S, Wirth W, et al. One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status. Ann Rheum Dis 2009;68:674-679.
29. Hussain H, Chenevert T, Londy F, et al. Hepatic fat fraction: MR imaging for quantitative measurement and display-early experience. Radiology 2005;237:1048-1055.
30. Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging 2008;28:543-558.
31. Reeder S, Pineda A, Wen Z, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med 2005;54:636-644.
32. Rakow-Penner R, Daniel B, Yu H, Sawyer-Glover A, Glover G. Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL. J Magn Reson Imaging 2006;23:87-91.
33. O'Regan D, Callaghan M, Wylezinska-Arridge M, et al. Liver fat content and T2*: simultaneous measurement by using breathhold multiecho MR imaging at 3.0T-feasibility. Radiology 2008; 247:550-557.
34. Bernard C, Liney G, Manton D, Turnbull L, Langton C. Comparison of fat quantification methods: a phantom study at 3.0T. J Magn Reson Imaging 2008;27:192-197.
35. Yu H, Shimakawa A, McKenzie C, Brodsky E, Brittain J, Reeder S. Multiecho Water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008;60:1122-1134.
36. Ashton E, Durkin E, Kwok E, Evelhoch J. Conversion from signal intensity to Gd concentration may be unnecessary for perfusion assessment of tumors using DCE-MRI. In: Proceedings of the 15th Annual Meeting of ISMRM, Berlin, 2007. (abstract 2813).
37. Chu B, Zhao X, Saam T, et al. Feasibility of in vivo, multicontrast-weighted MR imaging of carotid atherosclerosis for multicenter studies. J Magn Reson Imaging 2005;21:809-817.
38. Lieberman J, Tollefson G, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-370.
39. Bakshi R, Benedict R, Bermel R, et al. T2 Hypointensity in the deep gray matter of patients with multiple sclerosis. Arch Neurol 2002;59:62-68.
40. Ashton E. Widespread functional and molecular imaging in drug development. Expert Opin Drug Discov 2007;2:1477-1485.
41. Ashton E. Quantitative medical imaging. J Imaging Sci Technol 2007;51:117-121.
42. Eckstein F, Westhoff J, Sittek H, et al. In vivo reproducibility of three-dimensional cartilage volume and thickness measurements with MR Imaging. AJR Am J Roentgenol 1998;170:593-597.
43. Wluka A, Stuckey S, Snaddon J, Cicuttini F. The determinants of change in tibial cartilage volume in osteoarthritic knees. Arthritis Rheum 2002;46:2065-2072.
44. Qvist P, Bay-Jensen A, Christiansen C, Dam E, Pastoureau P, Karsdal M. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? Pharmacol Res 2008;58:1-7.
45. Temenoff J, Mikos A. Review: tissue engineering for regeneration of articular cartilage. Biomaterials 2000;21:431-440.
46. Dardzinski B, Mosher T, Li S, Van Slyke M, Smithe M. Spatial variation of T2 in human articular cartilage. Radiology 1997;205: 546-550.
47. David-Vaudey E, Ghosh S, Ries M, Majumdar S. T2 relaxation time measurements in osteoarthritis. Magn Reson Imaging 2004; 22:673-682.
48. Bashir A, Gray M, Hartke J, Burstein D. Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med 1999;41:857-865.
49. Tiderius J, Olsson L, Leander P, Ekberg O, Dahlberg L. Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) in early knee osteoarthritis. Magn Reson Med 2003;49:488-492.
50. Maier C, Tan S, Hariharan H, Potter H. T2 quantitation of articular cartilage at 1.5 T. J Magn Reson Imaging 2003;17:358-364.
51. Riek J, Ashton E.Use of a dual-echo fast-spin-echo sequence for T2 mapping of cartilage within a clinical trial. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 3988).
52. Trattnig S, Marlovits S, Gebetsroither S, et al. Three-dimensional delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) for in vivo evaluation of reparative cartilage after matrix-associated autologous chondrocyte transplantation at 3.0T: preliminary results. J Magn Reson Imaging 2007;26:974-982.
53. Kimelman T, Vu A, Storey P, McKenzie C, Burstein D, Prasad P. Three-dimensional t1 mapping for dGEMRIC at 3.0T using the look locker method. Invest Radiol 2006;41:198-203.
54. Evelhoch J. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
55. Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004;51:858-862.
56. Landau H. Sampling, data transmission, and the Nyquist rate. Proc IEEE 1967;55:1701-1706.
57. Roberts H, Roberts T, Lee T, Dillon W. Dynamic, contrastenhanced CT in human brain tumors: quantitative assessment of blood volume, blood flow, and microvascular permeability. AJNR Am J Neuroradiol 2002;23:828-832.
58. Jayson G, Parker G, Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23: 973-981.
59. Weinmann H, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-172.
60. Padhani A, Hayes C, Landau S, Leach M. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002;15:143-153.
61. Cenic A, Nabavi D, Craen R, Gelb A, Lee T. A dynamic CT method to measure cerebral blood flow in brain tumors: validation and application to CBF maps. AJNR Am J Neuroradiol 2000;21: 462-470.